natgillin/translations-raw huggingface dataset:
4.4 Særlige advarsler og forsigtighedsregler vedrørende brugen Eliminationen af prucaloprid sker hovedsagligt gennem renal udskillelse (se pkt.
Renal excretion is the main route of elimination of prucalopride (see section 5.2).
Ældre personer (> 65 år): Start med 1 mg én gang dagligt (se pkt.
Older people (>65 years): Start with 1 mg once daily (see section 5.2); if needed the dose can be increased to 2 mg once daily.
Andelen af kvindelige patienter, hvor laksantia ikke giver tilstrækkelig lindring, som opnåede i gennemsnit ≥ 3 SCBM pr. uge, var 31,0 % (uge 4) og 24,7 % (uge 12) ved behandling med den anbefalede dosis på 2 mg Resolor (n=458) vs. 8,6 % (uge 4) og 9,2 % (uge 12) i placebogruppen.
The proportion of female patients in whom laxatives fail to provide adequate relief treated with the recommended dose of 2 mg Resolor (n=458) that reached an average of ≥3 SCBM per week was 31.0% (week 4) and 24.7% (week 12), versus 8.6% (week 4) and 9.2% (week 12) on placebo.
Ved uge 12 havde 68,3 % af patienterne i behandling med 2 mg Resolor en gennemsnitlig stigning på ≥1 SBM/uge vs. 37,0 % af placebopatienterne (p<0,001 vs. placebo).
At week 12, 68.3% of patients treated with 2 mg Resolor had an average increase of ≥1 SBM/week versus 37.0% of placebo patients (p<0.001 vs placebo).
Ved uge 4 var andelen af patienter med en forbedring på ≥1 vs. baseline i PAC-SYM-delskalaerne for abdominal-, afførings- og rektalsymptomer hhv. 41,3 %, 41,6 % og 31,3 % hos patienter i behandling med 2 mg Resolor, sammenlignet med hhv. 26,9 %, 24,4 % og 22,9 % hos patienter på placebo.
At week 4, the proportion of patients with an improvement of ≥1 versus baseline in the PAC-SYM abdominal, stool, and rectal symptom subscales was 41.3%, 41.6%, and 31.3% respectively in patients treated with Resolor 2 mg compared with 26.9%, 24.4% and 22.9% in patients on placebo.
Dette stemmer ikke overens med de 5 andre 12-ugers randomiserede, dobbeltblindede, placebokontrollerede multicenterstudier, der påviste effekt på dette tidspunkt hos voksne patienter.
The difference between treatment groups in the average weekly frequency of ≥3 SCBMs per week was not statistically significant over Weeks 1-12 which is inconsistent with the 5 other multicentre, randomised, double-blind, 12-week placebo controlled studies demonstrating efficacy at this timepoint in adult patients.
Hvide til råhvide, runde, bikonvekse tabletter mærket med 'PRU 1' på den ene side.
White to off-white, round, biconvex tablets marked “PRU 1” on one side.
Opkastning, dyspepsi, flatulens, unormale tarmlyde
Vomiting, dyspepsia, flatulence, gastrointestinal sounds abnormal
Resolor 1 mg filmovertrukne tabletter Resolor 2 mg filmovertrukne tabletter prucaloprid
Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride
Prucaloprid kan udskilles i mælken ved amning.
When breast-feeding, prucalopride can pass into breast milk.
Nedsat nyrefunktion
Rectal haemorrhage
Én filmovertrukken tablet Resolor 2 mg indeholder 2 mg prucaloprid (som succinat).
One film-coated tablet of Resolor 2 mg contains 2 mg prucalopride (as succinate).
Én filmovertrukken tablet Resolor 1 mg indeholder 1 mg prucaloprid (som succinat).
One film-coated tablet of Resolor 1 mg contains 1 mg prucalopride (as succinate).
Tabletovertræk:
Tablet coating
Resolor 2 mg filmovertrukne tabletter
Resolor 2 mg film-coated tablets
Resolor 1 mg filmovertrukne tabletter er hvide til råhvide, runde tabletter mærket med 'PRU 1' på den ene side.
What Resolor looks like and contents of the pack Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked “PRU 1” on one side.
Der forventes ingen påvirkning af nyfødte børn/spædbørn ammet af kvinder, der har taget terapeutiske doser af Resolor.
At therapeutic doses of Resolor, no effects on breast-fed newborns/infants are anticipated.
Resolor 2 mg tabletter prucaloprid
Resolor 2 mg tablets prucalopride
Resolor 1 mg tabletter prucaloprid
Resolor 1 mg tablets prucalopride
Bivirkning
Incidence Category
Resolor 1 mg filmovertrukne tabletter
Resolor 1 mg film-coated tablets.
Det skal du vide, før du begynder at tage Resolor Sådan skal du tage Resolor Bivirkninger
What Resolor is and what it is used for What you need to know before you take Resolor How to take Resolor
Hver filmovertrukken tablet indeholder 2 mg prucaloprid (som succinat).
Each film-coated tablet contains 2 mg prucalopride (as succinate).
Hver filmovertrukken tablet indeholder 1 mg prucaloprid (som succinat).
Each film-coated tablet contains 1 mg prucalopride (as succinate).
Resolor 2 mg filmovertrukne tabletter prucaloprid
Resolor 2 mg film-coated tablets prucalopride
Resolor 1 mg filmovertrukne tabletter prucaloprid
Resolor 1 mg film-coated tablets prucalopride
EU/1/09/581/004 (7 tabletter) EU/1/09/581/006 (14 tabletter) EU/1/09/581/002 (28 (tabletter) EU/1/09/581/008 (84 tabletter)
EU/1/09/581/004 (7 tablets) EU/1/09/581/006 (14 tablets) EU/1/09/581/002 (28 tablets) EU/1/09/581/008 (84 tablets)
EU/1/09/581/001 (28 tabletter) EU/1/09/581/003 (7 tabletter) EU/1/09/581/005 (14 tabletter) EU/1/09/581/007 (84 tabletter)
EU/1/09/581/001 (28 tablets) EU/1/09/581/003 (7 tablets) EU/1/09/581/005 (14 tablets) EU/1/09/581/007 (84 tablets)
EU/1/09/581/002 (28 tabletter) EU/1/09/581/004 (7 tabletter) EU/1/09/581/006 (14 tabletter) EU/1/09/581/008 (84 tabletter)
EU/1/09/581/002 (28 tablets) EU/1/09/581/004 (7 tablets) EU/1/09/581/006 (14 tablets) EU/1/09/581/008 (84 tablets)
EU/1/09/581/001 (7 tabletter) EU/1/09/581/003 (14 tabletter) EU/1/09/581/001 (28 tabletter) EU/1/09/581/007 (84 tabletter)
EU/1/09/581/003 (7 tablets) EU/1/09/581/005 (14 tablets) EU/1/09/581/001 (28 tablets) EU/1/09/581/007 (84 tablets)
Iffeza 50 Mikrogramm/5 Mikrogramm pro Sprühstoß
Iffeza 50 Mikrogramm/5 Mikrogramm pro Sprühstoß Druckgasinhalation
Iffeza 125 Mikrogramm/5 Mikrogramm pro Sprühstoß
Iffeza 125 Mikrogramm/5 Mikrogramm pro Sprühstoß Druckgasinhalation
10 hætteglas 0 dage
10 bottles Zero days
10 flasker
10 glass vials
Der skal indsendes en opdateret version af risikostyringsplanen til de nationale kompetente myndigheder senest tre måneder efter Kommissionens afgørelse for denne procedure for at afspejle den opdaterede information vedrørende den pædiatriske population, som vedtaget af CHMP.
An updated version of the Risk Management Plan will be submitted to National Competent Authorities within 3 months of the Commission Decision for this procedure, to reflect the updated information on the paediatric population as agreed by CHMP.
Betingelser for markedsføringstilladelserne
Conditions of the marketing authorisations
De nationale kompetente myndigheder skal sikre, at følgende betingelser bliver opfyldt af indehaverne af markedsføringstilladelserne, om relevant under koordination af referencemedlemsstaten.
National Competent Authorities (NCAs), coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders (MAHs):
* p-værdi henviser til sammenligning mellem arme.
*p-value refers to comparison between arms.
Du vil normalt få infusionen én gang hver 3. uge.
You should usually receive your infusion once every 3 weeks.
• Stabil sygdom (%)
• Stable disease (%)
* Definition af hyppighed: Meget almindelig - ≥ 10 %; Almindelig > 5 % og < 10 %.
*Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%.
Dette svarer til 2,7 % af den anbefalede maximale daglige indtagelse af natrium for en voksen.
This is equivalent to 2.7% of the recommended maximum daily dietary intake of sodium for an adult.
Da der ikke foreligger studier af eventuelle uforligeligheder, må dette lægemiddel ikke blandes med andre lægemidler.
In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products.
Fishers eksakte pniveau*
Fisher's exact pvalue*
• P-værdi for non-inferioritet (HR)
• Non-inferiority p-value (HR)
Hver æske indeholder ét hætteglas.
Each box contains one vial.
** som stammer fra udtrykket ”andre renale/genitourinære faktorer”.
** which is derived from the term “renal/genitourinary other”.
Forkortelse: CI = konfidensinterval.
Abbreviation: CI = confidence interval.
Din læge vil sammen med dig drøfte den potentielle risiko ved at tage Pemetrexed Krka under graviditet.
Your doctor will discuss with you the potential risk of taking Pemetrexed Krka during pregnancy.
Ud fra den planlagte dato for din infusion af Pemetrexed Krka og/eller status for din nyrefunktion skal din læge fortælle dig, hvilke typer medicin du må tage, og hvornår du må tage dem.
Based on the planned date of your infusion of Pemetrexed Krka and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Den 1-årige og 2årige overlevelsesrate for patienterne i behandling med pemetrexed var henholdsvis 58 % og 32 % sammenlignet med 45 % og 21 % for patienterne i placebo-behandling.
The 1 year and 2 year survival rates for patients on pemetrexed were 58% and 32% respectively, compared to 45% and 21% for patients on placebo.
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du fortælle det til din læge.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor.
Total-bilirubin skal være 1,5 gange den normale øvre grænseværdi.
The total bilirubin should be ≤ 1.5-times upper limit of normal.
Sikkerheden blev vurderet for de patienter, som blev randomiseret til pemetrexed (n = 800).
Safety was assessed for patients who were randomised to receive pemetrexed (N=800).
Almindelig Nyresygdomme**** 7,6
Common Renal disorders**** 7.6
Der er ingen data fra anvendelse af pemetrexed til gravide kvinder, men ligesom andre antimetabolitter formodes pemetrexed at kunne forårsage alvorlige misdannelser, hvis det indgives under graviditeten.
There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other antimetabolites, is suspected to cause serious birth defects when administered during pregnancy.
Statistisk signifikans for non-inferioritet med hele konfidensintervallet for HR pænt under 1,17645 for non-inferioritet-margin (p < 0,001).
a Statistically significant for non-inferiority, with the entire confidence interval for HR well below the 1.17645 non-inferiority margin (p < 0.001).
Der er ikke foretaget undersøgelser af påvirkningen af evnen til at køre bil og betjene maskiner.
No studies on the effects on the ability to drive and use machines have been performed.
Du vil altid få Pemetrexed Krka ved infusion i en af dine blodårer.
You will always receive Pemetrexed Krka by infusion into one of your veins.
Brug en inaktiveret vaccine, hvis muligt (poliomyelitis) (se pkt.
Use an inactivated vaccine where it exists (poliomyelitis) (see section
Forkortelser: ALAT = alanin-aminotransferase; ASAT = aspartat-aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamin-oksalsyre-aminotransaminase; SGPT = serum glutamate-pyruvat-aminotransaminase.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Pakning med 1 hætteglas i en æske.
Pack of 1 vial is available in a box.
Undtagen neurotoksicitet
Excluding neurotoxicity
Randomiseret og behandlet
Randomised and treated patients
Cisplatin indgives også ved infusion i en af dine blodårer, cirka 30 minutter efter at infusionen med Pemetrexed Krka er afsluttet.
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Krka has finished.
Efter rekonvalescens skal patienter efterbehandles ud fra retningslinjerne i tabel 1, 2 og 3, der gælder for brug af Pemetrexed Krka som enkeltstof eller i kombination med cisplatin.
Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for Pemetrexed Krka used as a single agent or in combination with cisplatin.
Patienter skal derfor have modtaget passende anti-emetisk behandling og relevant hydrering inden og/eller efter behandlingen.
Therefore, patients should receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving treatment.
- Immun-medieret hæmolytisk anæmi (antistof-medieret ødelæggelse af de røde blodlegemer) - Leverbetændelse (hepatitis) - Anafylaktisk shock (alvorlig allergisk reaktion)
- Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) - Hepatitis (inflammation of the liver) - Anaphylactic shock (severe allergic reaction)
- Allergisk reaktion: Hvis du udvikler udslæt (meget almindelig)/en brændende eller prikkende fornemmelse (almindelig) eller feber (almindelig).
- Allergic reaction: if you develop skin rash (very common) / burning or prickling sensation (common), or fever (common).
Dette kortikosteroid-præparat skal svare til 4 mg dexamethason indgivet oralt 2 gange dagligt (se pkt 4.4).
The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section 4.4).
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med pemetrexed i alle undergrupper af den pædiatriske population for de godkendte indikationer (se pkt 4.2 for oplysninger om pædiatrisk anvendelse).
The European Medicines Agency has waived the obligation to submit the results of studies with pemetrexed in all subsets of the paediatric population in the granted indications (see section 4.2).
Du skal omgående kontakte din læge, hvis du mærker nogen af følgende bivirkninger: - Feber eller infektion (almindelig): Hvis din temperatur er 38 ºC eller højere, hvis du sveder eller viser andre tegn på infektion (fordi du muligvis har færre hvide blodlegemer end normalt, hvilket er meget almindeligt).
You must contact your doctor immediately if you notice any of the following: - Fever or infection (common): if you have a temperature of 38°C or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common).
Denne dosis skal muligvis justeres, eller behandlingen skal udskydes, afhængigt af dine blodtal og generelle tilstand.
This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.
Rekonstituerede opløsninger og infusionsopløsninger af pemetrexed har vist sig at have en kemisk og fysisk holdbarhed på 24 timer ved temperaturer på 2 °C-8 °C (og 25 °C).
Chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at 2°C to 8°C (and 25°C).
** I pemetrexed/cisplatin-armen, randomiseret og behandlet (n = 225) og fuldt tilskud (n = 167)
**In the pemetrexed/cisplatin arm, randomized and treated (N=225) and fully supplemented (N=167).
Dato for første markedsføringstilladelse: 22. maj 2018
Date of first authorisation: 22.
Advarsler og forsigtighedsregler Kontakt lægen eller hospitalsapoteket, før du bruger Pemetrexed Krka.
Warnings and precautions Talk to your doctor or hospital pharmacist before using Pemetrexed Krka.
** Se NCI CTCAE Criteria (Version 3.0; NCI 2003) for hver toksicitetsgrad.
**Refer to NCI CTCAE Criteria (Version 3.0; NCI 2003) for each grade of toxicity.
Der er kun rapporteret enkelte tilfælde af ekstravasation af pemetrexed, som investigatoren ikke betragtede som alvorlige.
There have been a few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator.
I tilfælde af neurotoksicitet er den anbefalede dosisjustering for Pemetrexed Krka og cisplatin angivet i tabel 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Krka and cisplatin is documented in Table 3.
Se punkt 2 ”Pemetrexed Krka indeholder natrium”.
See section 2 "Pemetrexed Krka contains sodium".
Før hver indgivelse vil du få taget blodprøver til vurdering af, om din nyre- og leverfunktion er tilstrækkelig god, og for at kontrollere, om du har blodlegemer nok til at få Pemetrexed Krka.
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Krka.
Yderligere oplysninger om dette lægemidde findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Kortikosteroider: Din læge vil udskrive steroidtabletter til dig (svarende til 4 milligram dexamethason 2 gange dagligt), som du skal tage dagen før, på behandlingsdagen og dagen efter behandling med Pemetrexed Krka.
Corticosteriods: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Pemetrexed Krka treatment.
Almindelig Pruritus Alopeci
Common Pruritus Alopecia
Pemetrexed Krka må ikke anvendes under graviditet.
The use of Pemetrexed Krka should be avoided during pregnancy.
**** Den kombinerede term omfatter forøget serum/blod-kreatinin, nedsat glomerulær filtrationshastighed, nyresvigt og andre renale/genitourinale faktorer.
****Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other.
Hvis produktet ikke anvendes med det samme, er det brugerens ansvar at vurdere holdbarheden og opbevaringsforholdene, inden produktet anvendes, og holdbarheden vil højst være 24 timer ved 2 C-8 C.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C to 8°C.
Farmakoterapeutisk klassifikation: Antineoplastiske stoffer, folsyreanaloger, ATC-kode L01BA04.
Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04.
Der skal derfor udvises forsigtighed ved indgift af højere doser af NSAID-præparater eller acetylsalicylsyre samtidig med pemetrexed hos patienter med normal nyrefunktion (kreatinin-clearance 80 ml/min).
Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Alkalisk fosfatase, ASAT og ALAT  5 gange den normale øvre grænseværdi er acceptabelt, hvis patientens lever er beskadiget af tumor.
Alkaline phosphatase, AST and ALT ≤ 5-times upper limit of normal is acceptable if liver has tumour involvement.
* Se National Cancer Institute CTC-version 2 for hver grad af toksicitet, undtagen udtrykket ”nedsat kreatinin-clearance”.
* Refer to National Cancer Institute CTC version 2 for each grade of toxicity except the term “creatinine clearance decreased”
Pemetrexeds farmakokinetiske egenskaber efter enkeltstofadministration er blevet vurderet hos 426 cancerpatienter med forskellige typer massive tumorer i doser på 0,2-838 mg/m2 infunderet over
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m2 infused over a 10-minute period.
Brug ikke Pemetrexed Krka - hvis du er allergisk over for pemetrexed eller et af de øvrige indholdsstoffer dette lægemiddel
Do not use Pemetrexed Krka - if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6).
Ikke almindelig (≥1/1.000 til <1/100) Sjælden (≥1/10.000 til <1/1.000) Meget sjælden (<1/10.000)
Frequency estimate: - Very common (1/10) - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data)
* Se National Cancer Institute CTC-version 2 for hver grad af toksicitet.
*Refer to National Cancer Institute CTC version 2 for each grade of toxicity.
I kliniske studier krævede patienter med en kreatinin-clearance på 45 ml/min ingen særlige dosisjusteringer ud over de, der anbefales til alle patienter.
In clinical studies, patients with creatinine clearance of ≥ 45 ml/min required no dose adjustments other than those recommended for all patients.
Hvis du har en væskeansamling omkring lungerne, vil lægen muligvis beslutte at fjerne denne væske, før du modtager behandling med Pemetrexed Krka.
If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed Krka.
Forkortelser: CI = konfidensinterval; HR = hazard-ratio; ITT = intent to treat; n = samlet populationsstørrelse.
Abbreviations: CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; N = total population size.
Du skal tage mindst 5 doser i løbet af de 7 dage op til den første dosis Pemetrexed Krka.
You must take at least 5 doses during the seven days before the first dose of Pemetrexed Krka.
Almindelig Opkastning Mucositis/stomatitis
Common Vomiting Mucositis/Stomatitis
Incidensen af bivirkninger blev evalueret for de patienter, som fik ≤ 6 serier af pemetrexedvedligeholdelsesbehandling (n = 519), og sammenlignet med de patienter, som fik > 6 serier pemetrexed (n = 281).
The incidence of adverse reactions was evaluated for patients who received ≤6 cycles of pemetrexed maintenance (N=519), and compared to patients who received >6 cycles of pemetrexed (N=281).
Pemetrexed Krka er et lægemiddel, der anvendes til behandling af kræft.
Pemetrexed Krka is a medicine used in the treatment of cancer.
Der blev observeret en signifikant øget forekomst af grad 3/4 neutropeni, som muligvis var relateret til studiemedicinen, ved længere eksponering for pemetrexed (≤ 6 serier: 3,3 %; > 6 serier: 6,4 %; p = 0,046).
A significant increase in the incidence of possibly study-drug-related Grade 3/4 neutropenia was observed with longer exposure to pemetrexed (≤6 cycles: 3.3%, >6 cycles: 6.4%: p=0.046).
Bivirkninger med Pemetrexed Krka kan være:
Side effects with Pemetrexed Krka may include:
- Hvis du har smerter, rødmen, hævelse eller sår i munden (meget almindelig).
- If you have pain, redness, swelling or sores in your mouth (very common).
Det er et hvidt til lysegult eller grøngult frysetørret kage eller pulver.
It is a white to either light yellow or green yellow lyophilized cake or powder.
Under behandlingen skal patienten monitoreres for myelosuppression, og pemetrexed må ikke gives til patienter, før det absolutte neutrofiltal (ANC) igen er 1.500 celler/mm
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1,500 cells/mm
Du skal fortsætte med at tage folsyre i 21 dage efter indgift af den sidste dosis Pemetrexed Krka.
You must continue taking the folic acid for 21 days after the last dose of Pemetrexed Krka.
Du vil også få en injektion med B12-vitamin (1.000 mikrogram) i løbet af ugen op til første dosis Pemetrexed Krka og derefter cirka hver 9. uge (svarende til 3 Pemetrexed Krka-behandlingsforløb).
You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administration of Pemetrexed Krka and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed Krka treatment).
Beregn den nødvendige dosis og det nødvendige antal hætteglas med Pemetrexed Krka.
Calculate the dose and the number of Pemetrexed Krka vials needed.
Pemetrexed Krka kan muligvis gøre dig træt.
Driving and using machines Pemetrexed Krka may make you feel tired.
Før påbegyndelse af en kemoterapiserie skal patienter opfylde følgende parametre: Det absolutte neutrofiltal (ANC) skal være 1.500 celler/mm
Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be ≥ 1500 cells/mm